TVGN_OUT_1 [2025-04-28 18:08:34 -0400] 5805 Bytes | 1557 tokens | Cum: 1557 tkns (19.46% of 8k)
==========================================================================

We're scouting for winners today. Its 6:08 PM on Mon Apr 28, 2025 and I'm looking at Tevogen Bio (TVGN) up to $1.28 from $0.9922

Help me investigate to see if its got potential or just another dud. So, I pulled together a bunch of data for you to look over real fast.

--- COMPANY PROFILE ---
Company: Tevogen Bio (TVGN)
IPO: IPO date unknown
Shares Outstanding: 183,890,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS

Here’s a list of headlines for Tevogen Bio:

Today 04:36PM - Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion
Apr-25-25 02:33PM - Tevogen Bio Announces 2025 Annual Meeting
Apr-17-25 02:54PM - Tevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production Facility
Apr-16-25 08:58AM - WHO and WEF Are Pushing AI in Global Healthcare -- What It Means for the Market
Apr-15-25 02:03PM - Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction
Apr-14-25 01:53PM - Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald
Apr-11-25 04:00PM - Tevogen Bio Holdings: Initiating Sell Rating Based On Pipeline Uncertainty And Cash Constraints
Apr-09-25 02:45PM - Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump's Initiative to Encourage Pharmaceutical Manufacturing in United States
Apr-08-25 05:53PM - Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly's Leading AI Biotechs
Apr-07-25 03:58PM - Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company's Mission
Mar-26-25 03:12PM - Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast
Mar-25-25 01:11PM - Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan
Mar-10-25 12:40PM - Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO
Mar-07-25 04:09PM - Tevogen Bio's CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer's AI Discussion Panel
Mar-03-25 12:52PM - Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations
Feb-28-25 01:17PM - Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy
Feb-21-25 03:28PM - Tevogen Bio's First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned
Feb-14-25 06:31PM - Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision
Feb-14-25 06:31PM 01:16PM - Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency
Feb-14-25 06:31PM 11:52AM - Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation's Health and Prosperity
Feb-13-25 04:34PM - Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans
Feb-10-25 05:30PM - Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-04-25T18:33:00Z - Tevogen Bio Announces 2025 Annual Meeting
B2 - 2025-04-17T18:54:18Z - Tevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production Facility
B3 - 2025-04-17T18:54:00Z - Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility
B4 - 2025-04-14T17:53:00Z - Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald
B5 - 2025-04-09T18:45:00Z - Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump’s Initiative to Encourage Pharmaceutical Manufacturing in United States
B6 - 2025-04-08T21:53:00Z - Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly’s Leading AI Biotechs

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Tevogen Bio (TVGN).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

TVGN_OUT_3 [2025-04-28 18:08:35 -0400] 919 Bytes | 226 tokens | Cum: 1785 tkns (22.31% of 8k)
==========================================================================

Showing B2 (chunk 1 of 1): B2:
**Tevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production Facility**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/pressreleases/25/04/g44875045/tevogen-bio-finalizes-agreement-for-companys-own-cell-therapy-production-facilityTevogen Bio has entered into an agreement with CD 8 Technology Services LLC to develop and/or acquire a turn-key facility to support in-house pre-clinical research and GMP cell therapy production capabilities. This agreement is a key component of Tevogen Bio's long-term strategy to accelerate development timelines, maintain operational agility, and control costs.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

TVGN_OUT_5 [2025-04-28 18:08:36 -0400] 1039 Bytes | 308 tokens | Cum: 2095 tkns (26.19% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-28T21:30:27Z - Tevogen Bio Holdings Stock Is Soaring After Hours: What's Going On? - Tevogen Bio Holdings (NASDAQ:T...
A2 - 2025-04-28T20:36:00Z - Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Y...
A3 - 2025-04-28T21:05:47Z - 12 Health Care Stocks Moving In Monday's After-Market Session - Autonomix Medical (NASDAQ:AMIX), Ana...
A4 - 2025-04-28T21:04:57Z - Tevogen Bio (TVGN) Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cum...
A5 - 2025-04-28T20:44:58Z - Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Y...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

TVGN_OUT_7 [2025-04-28 18:08:37 -0400] 1181 Bytes | 307 tokens | Cum: 2404 tkns (30.05% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**Tevogen Bio Holdings Stock Is Soaring After Hours: What's Going On? - Tevogen Bio Holdings (NASDAQ:TVGN)**Date: 2025-04-28Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/general/biotech/25/04/45055095/tevogen-bio-holdings-stock-is-soaring-after-hours-whats-going-onTevogen Bio Holdings Inc TVGN shares are ripping higher in Monday's after-hours session after the company reaffirmed its oncology pipeline revenue forecast.

What Happened: After the market close on Monday, Tevogen Bio reaffirmed its oncology pipeline outlook, forecasting $1 billion in revenue in its launch year. The company also projected cumulative five-year estimated sales in the range of $10 billion and $14 billion.

"With our intellectual property secured, Tevogen continues to build its U.S.-based cell therapy manufacturing capabilities, and I look forward to upda

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

TVGN_OUT_9 [2025-04-28 18:08:38 -0400] 1181 Bytes | 281 tokens | Cum: 2687 tkns (33.59% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): ting our shareholders on our forecasts and internal assets valuation," said Ryan Saadi, founder and CEO of Tevogen Bio.

Tevogen Bio had a market cap of approximately $173.7 million as of Monday's close. The company is set to hold its 2025 annual meeting of stockholders on June 23.

Check This Out: Amkor Technology Shares Climb After Q1 Revenue Beats, Q2 Revenue Guidance Above Estimates

How To Buy TVGN Stock

By now you're likely curious about how to participate in the market for Tevogen Bio -- be it to purchase shares, or even attempt to bet against the company.

Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here.

If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform or a broker who will allow you to "go short" a share of stock by lending you the shares

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

TVGN_OUT_11 [2025-04-28 18:08:38 -0400] 1052 Bytes | 269 tokens | Cum: 2958 tkns (36.98% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading -- either way it allows you to profit off of the share price decline.

TVGN Price Action: Tevogen Bio shares were up 39.76% after-hours, trading at $1.31 at the time of publication Monday, according to Benzinga Pro data.

Photo: T. Schneider/Shutterstock.

TVGNTevogen Bio Holdings Inc$1.3031.0%Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock - anytime.

Reveal Full ScoreEdge RankingsMomentum16.39Price TrendShortMediumLongOverviewMarket News and Data brought to you by Benzinga APIs

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

TVGN_OUT_13 [2025-04-28 18:08:39 -0400] 1069 Bytes | 298 tokens | Cum: 3258 tkns (40.73% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-17 8-K Item 7.01 Regulation FD Disclosure.

On April 17, 2025, Tevogen Bio Holdings Inc. (Tevogen) entered into a Master Services and Facilities Agrmt (the Agrmt) with CD 8 Technology Services LLC (CD8). The Agrmt establishes the general terms and conditions under which CD8...

S2 - 2025-04-02 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

You should read the following discussion and analysis of our financial condition and results of operations together with our audited CONS financial statements and related note...

S6 - 2024-11-19 10-Q PART I FIN INFO

Item 1. Fin Stmnts (Unaudited)

Tevogen Bio Holdings Inc.

UNAUDITED CONS BAL SHEETS

September 30, December 31, 2024 2023 Assets Curr assets: Cash $ 2,330,681 $ 1,052,397 Prepaid expenses and other assets 1,038,217 670...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

TVGN_OUT_15 [2025-04-28 18:08:40 -0400] 1181 Bytes | 265 tokens | Cum: 3525 tkns (44.06% of 8k)
==========================================================================

Showing S1 (chunk 1 of 2): S1:
Item 7.01 Regulation FD Disclosure.

On April 17, 2025, Tevogen Bio Holdings Inc. (Tevogen) entered into a Master Services and Facilities Agreement (the Agreement) with CD 8 Technology Services LLC (CD8). The Agreement establishes the general terms and conditions under which CD8 would provide Tevogen with access to specialized manufacturing facilities, including clean rooms and laboratories, as well as related operational services, to support the production of Tevogens cell therapy products. The Agreement provides that the specific details of these facilities and services, including scope of work, costs, and timelines, will be set out in one or more individual project work orders. The Agreement has an initial term of 12 months and will automatically renew for additional 12-month periods unless it is terminated in accordance with the terms set forth therein. CD8 is associated with Dr

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

TVGN_OUT_17 [2025-04-28 18:08:40 -0400] 570 Bytes | 155 tokens | Cum: 3682 tkns (46.02% of 8k)
==========================================================================

Showing S1 (chunk 2 of 2): . Manmohan Patel, who beneficially owns more than 5% of Tevogens common stock.

On April 17, 2025, Tevogen issued a press release announcing the Agreement. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference....

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

TVGN_OUT_19 [2025-04-28 18:08:49 -0400] 8058 Bytes | 2092 tokens | Cum: 5776 tkns (72.20% of 8k)
==========================================================================

This is our set of metrics for Tevogen Bio.
Please analyze the numbers.

+-------------------+-----------------------+------------------------+-------------------+
| Volume: 3,603,611 | Perf Month: -21.88% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+-------------------+-----------------------+------------------------+-------------------+
| Avg Volume: 1.68M | Perf Quarter: -44.20% | Short Float: 5.45% | ROE: -124.74% |
+-------------------+-----------------------+------------------------+-------------------+
| Rel Volume: 2.15 | Index: RUT | Short Ratio: 0.87 | ROI: - |
+-------------------+-----------------------+------------------------+-------------------+
| RSI (14): 39.93 | Market Cap: 172.38M | Short Interest: 1.46M | Sales Surprise: - |
+-------------------+-----------------------+------------------------+-------------------+
| ATR (14): 0.09 | Shs Outstand: 177.99M | Beta: -0.77 | EPS Surprise: - |
+-------------------+-----------------------+------------------------+-------------------+
| SMA20: -8.10% | Shs Float: 26.87M | Sales Q/Q: - | P/E: - |
+-------------------+-----------------------+------------------------+-------------------+
| SMA50: -18.68% | Inst Own: 1.30% | Sales past 5Y: 0.00% | Earnings: - |
+-------------------+-----------------------+------------------------+-------------------+
| SMA200: -12.47% | Insider Own: 85.39% | Employees: 18 | |
+-------------------+-----------------------+------------------------+-------------------+
| Perf Week: 0.55% | Insider Trans: -0.42% | Debt/Eq: - | |
+-------------------+-----------------------+------------------------+-------------------+

The next section covers any insider trading by Tevogen Bio officers or majority shareholders (if available).

Inside Trans: Tevogen Bio Holdings Inc. (TVGN) by Flomenberg Neal (See Remarks) on 2025-03-12
- Common Stock: 232968 shares at $1.09 (D) Footnote: The sales reported on this Form 4 were made solely to satisfy the payment of tax obligations relating to the vesting and subsequent settlement of restricted stock units. Such sales were not made at the discretion of the reporting person.

Inside Trans: Tevogen Bio Holdings Inc. (TVGN) by Flomenberg Neal (See Remarks) on 2025-03-07
- Common Stock: 71273 shares at $1.14 (D) Footnote: The sales reported on this Form 4 were made solely to satisfy the payment of tax obligations relating to the vesting and subsequent settlement of restricted stock units. Such sales were not made at the discretion of the Reporting Person.
- Common Stock: 70384 shares at $1.09 (D) Footnote: The sales reported on this Form 4 were made solely to satisfy the payment of tax obligations relating to the vesting and subsequent settlement of restricted stock units. Such sales were not made at the discretion of the Reporting Person.
- Common Stock: 70252 shares at $1.05 (D) Footnote: The sales reported on this Form 4 were made solely to satisfy the payment of tax obligations relating to the vesting and subsequent settlement of restricted stock units. Such sales were not made at the discretion of the Reporting Person.

Inside Trans: Tevogen Bio Holdings Inc. (TVGN) by Flomenberg Neal (See Remarks) on 2025-03-04
- Common Stock: 14639 shares at $1.28 (D) Footnote: The sales reported on this Form 4 were made solely to satisfy the payment of tax obligations relating to the vesting and subsequent settlement of restricted stock units. Such sales were not made at the discretion of the Reporting Person.
- Common Stock: 110659 shares at $1.21 (D) Footnote: The sales reported on this Form 4 were made solely to satisfy the payment of tax obligations relating to the vesting and subsequent settlement of restricted stock units. Such sales were not made at the discretion of the Reporting Person.
- Common Stock: 88519 shares at $1.1 (D) Footnote: The sales reported on this Form 4 were made solely to satisfy the payment of tax obligations relating to the vesting and subsequent settlement of restricted stock units. Such sales were not made at the discretion of the Reporting Person.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -5884223.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.9374
Average Volume: 834487.7
30-Day High: 1.12
30-Day Low: 0.9323

[Detailed Financials: Q3 2024]
- Total Assets: $4,289,472.00
- Total Liabilities: $10,479,941.00
- Total Equity: $-6,190,469.00
- Current Assets: $3,527,717.00
- Current Liabilities: $10,415,738.00

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: $-5,884,223.00
- Gross Profit: N/A
- Operating Income: $-6,085,527.00
- Earnings Per Share (EPS): -0.03

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $0.00

[Detailed Financials: Q2 2024]
- Total Assets: $3,310,259.00
- Total Liabilities: $10,944,156.00
- Total Equity: $-7,663,897.00
- Current Assets: $2,446,763.00
- Current Liabilities: $10,611,948.00

[Income Statement: Q2 2024]
- Revenue: $6.00
- Net Income: $-9,663,447.00
- Gross Profit: N/A
- Operating Income: $-8,599,027.00
- Earnings Per Share (EPS): -0.04

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $0.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Tevogen Bio (TVGN).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Tevogen Bio.

2) MARKET_SCORE[]
This conversation was initiated because TVGN is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for TVGN.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, TVGN could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect TVGN to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Tevogen Bio.

11) ETHICAL_RATING[]
Rate Tevogen Bio’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Tevogen Bio.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

TVGN_IN_21 [2025-04-28 18:08:49 -0400] 126 Bytes | 29 tokens | Cum: 6040 tkns (75.50% of 8k)
==========================================================================

====================================
[2025-04-28 18:08:49] # Analysis Completed
Elapsed Time: 16.00 seconds